Skip to Content

Brilique

Active Substance: ticagrelor
Common Name: ticagrelor
ATC Code: B01AC24
Marketing Authorisation Holder: AstraZeneca AB
Active Substance: ticagrelor
Status: Authorised
Authorisation Date: 2010-12-03
Therapeutic Area: Peripheral Vascular Diseases Acute Coronary Syndrome
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with

  • acute coronary syndromes (ACS) or
  • a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event
  • Brilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.

    What is Brilique?

    Brilique is a medicine that contains the active substance ticagrelor. It is available as tablets (60 and 90 mg).

    What is Brilique used for?

    Brilique is used together with aspirin (acetylsalicylic acid) to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) such as heart attacks or strokes. It is used in adults with acute coronary syndrome, a group of conditions in which blood flow in the vessels supplying the heart is blocked so heart tissue cannot work properly or dies, and which includes heart attack and unstable angina (a severe type of chest pain). Brilique is also used in adults who had a heart attack a year or more ago and are at a high risk of an atherothrombotic event.

    The medicine can only be obtained with a prescription.

    How is Brilique used?

    For patients with acute coronary syndrome, the starting dose of Brilique is two 90-mg tablets taken at once, followed by a regular dose of one 90-mg tablet twice a day. They should take Brilique for a year unless the doctor asks them to stop it earlier. For longer treatment, the dose of Brilique should be reduced to one 60-mg tablet twice a day.

    For patients who have had a heart attack a year or more ago (but less than 2 years ago) and are at high risk of an atherothrombotic event, the dose of Brilique is one 60-mg tablet twice a day. Patients taking Brilique should also be taking aspirin as directed by their doctor. The doctor may, for health reasons, tell them not to take aspirin. For further information, see the package leaflet.

    How does Brilique work?

    The active substance in Brilique, ticagrelor, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots, this is due to cell fragments in the blood called platelets aggregating (sticking together). Ticagrelor stops the platelets aggregating by blocking the action of a substance called ADP when it attaches to the surface of the platelets. This stops the platelets becoming ‘sticky’, reducing the risk of a blood clot forming and helping to prevent a stroke or another heart attack.

    How has Brilique been studied?

    Brilique was compared with clopidogrel (another inhibitor of platelet aggregation) in a main study involving over 18,000 adults who had had a heart attack or had unstable angina. The patients also took aspirin and were treated for up to a year.

    In another main study, Brilique was compared with placebo (a dummy treatment) in over 21,000 adults who had a heart attack one to three years previously and were at high risk of an atherothrombotic event. Patients took Brilique twice a day in a dose of either 60 mg or 90 mg. The patients also took aspirin and were treated for up to 3 years.

    The main measure of effectiveness for both studies was based on the number of patients having another heart attack, a stroke or dying from a cardiovascular disease.

    What benefit has Brilique shown during the studies?

    Brilique was shown to be beneficial to patients who have had a heart attack or unstable angina. In the first main study (in patients with acute coronary syndrome), 9.3% of the patients taking Brilique had another heart attack, stroke or died from a cardiovascular disease compared with 10.9% of patients taking clopidogrel.

    In the second main study (in patients with a history of the heart attack), 7.8% of patients taking Brilique 60 mg twice a day had another heart attack, stroke or died from cardiovascular disease compared with 9.0% of patients taking placebo.

    What is the risk associated with Brilique?

    The most common side effects with Brilique (seen in more than 1 patient in 10) are dyspnoea (difficulty breathing), bleeding and raised uric acid level in the blood. For the full list of all side effects reported with Brilique, see the package leaflet.

    Brilique must not be used in patients who have severe liver disease or are currently bleeding, or in patients who have had bleeding within the brain. It must also not be used in patients taking other medicines which have a strong blocking effect on one of the liver enzymes (CYP3A4). These are medicines such as ketoconazole (used to treat fungal infections), clarithromycin (an antibiotic), atazanavir and ritonavir (medicines used in HIV-positive patients) and nefazodone (used to treat depression). For the full list of restrictions with Brilique, see the package leaflet.

    Why has Brilique been approved?

    The CHMP decided that Brilique’s benefits are greater than its risks and recommended that it be given marketing authorisation.

    The CHMP considered that in patients with acute coronary artery syndrome, Brilique at a dose of 90 mg twice daily and given with aspirin, reduces the risk of atherothrombotic events such as heart attack, stroke and death from a cardiovascular event. Benefit regarding heart attack, stroke and death from a cardiovascular event has also been shown in patients who had a heart attack at least one year ago and have a high risk of an atherothrombotic event and a lower 60 mg dose twice daily dose is recommended for these patients.

    Other information about Brilique

    The European Commission granted a marketing authorisation valid throughout the European Union for Brilique on 3 December 2010.

    For more information about treatment with Brilique, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

    Source: European Medicines Agency

    Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

    Hide